Cancer researchers at several sites across the United States are seeking male volunteers newly diagnosed with high-risk prostate cancer, who are also candidates for surgery, to take part in a clinical trial on an experimental drug.The molecularly targeted drug called CCI779 may interrupt the signal that drives prostate cancer and may keep the disease from recurring. It’s been successfully tested in laboratory and animal models.
